Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma.
Ontology highlight
ABSTRACT: Glioblastoma (GBM) is a stage IV astrocytoma that carries a dismal survival rate of ≈10 months postdiagnosis and treatment. The highly invasive capacity of GBM and its ability to escape therapeutic challenges are key factors contributing to the poor overall survival rate. While current treatments aim to target the cancer cell itself, they fail to consider the significant role that the GBM tumor microenvironment (TME) plays in promoting tumor progression and therapeutic resistance. The GBM tumor glycocalyx and glycan-rich extracellular matrix (ECM), which are important constituents of the TME have received little attention as therapeutic targets. A wide array of aberrantly modified glycans in the GBM TME mediate tumor growth, invasion, therapeutic resistance, and immunosuppression. Here, an
SUBMITTER: Tondepu C
PROVIDER: S-EPMC9048137 | biostudies-literature | 2022 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA